Synergistic Anti-Tumor Responses After Administration of Agonistic Antibodies to CD40 and IL-2: Coordination of Dendritic and CD8+ Cell Responses 1

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Immunology

• Publication date

  2003-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.4049/jimmunol.170.5.2727PMID 12594303
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• IL-2 mediates adjuvant effect of dendritic cells.

  2002cited by this paper
• CD40 stimulation leads to effective therapy of CD40− tumors through induction of strong systemic cytotoxic T lymphocyte immunity

  2002cited by this paper
• Anti-CD40 Antibody Induces Antitumor and Antimetastatic Effects: The Role of NK Cells1

  2001cited by this paper
• Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma.

  2001cited by this paper
• Induction of transplantable mouse renal cell cancers by streptozotocin: in vivo growth, metastases, and angiogenic phenotype.

  2001cited by this paper
• CD40 Activates NF-κB and c-Jun N-Terminal Kinase and Enhances Chemokine Secretion on Activated Human Hepatic Stellate Cells1

  2001cited by this paper
• CD40 stimulation accelerates deletion of tumor-specific CD8+ T cells in the absence of tumor-antigen vaccination

  2001cited by this paper
• Inducible IL-2 production by dendritic cells revealed by global gene expression analysis

  2001cited by this paper
• Stimulation via CD40 can substitute for CD4 T cell function in preventing reactivation of a latent herpesvirus

  2001cited by this paper
• IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy.

  2001cited by this paper
• Analysis of the Requirements for the Induction of CD4+ T Cell Alloantigen Hyporesponsiveness by Ex Vivo Anti-CD40 Ligand Antibody1

  2000cited by this paper
• The Roles of CD28 and CD40 Ligand in T Cell Activation and Tolerance1

  2000cited by this paper
• Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction.

  2000cited by this paper
• Dendritic cells genetically modified to express CD40 ligand and pulsed with antigen can initiate antigen-specific humoral immunity independent of CD4+ T cells

  2000cited by this paper
• T lymphocyte and monocyte interaction by CD40 / CD40 ligand facilitates a lymphoproliferative response and killing of Cryptococcus neoformans in vitro

  2000cited by this paper
• Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40

  1999cited by this paper
• Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand.

  1999cited by this paper
• Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease.

  1999cited by this paper
• Functions of CD40 on B cells, dendritic cells and other cells.

  1997cited by this paper
• Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy.

  1996cited by this paper
• Induction of IL-12 p40 messenger RNA expression and IL-12 production of macrophages via CD40-CD40 ligand interaction.

  1996cited by this paper
• Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma.

  1996cited by this paper
• Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas.

  1996cited by this paper
• The Role of CD40 Ligand in Costimulation and T‐Cell Activation

  1996cited by this paper
• CD40 and its ligand.

  1996cited by this paper
• Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

  1995cited by this paper
• CD40 ligand is required for resolution of Pneumocystis carinii pneumonia in mice.

  1995cited by this paper
• CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40

  1993cited by this paper
• A B‐lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas.

  1989cited by this paper
• Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver.

  1985cited by this paper
• Establishment and characterization of BALB/c lymphoma lines with B cell properties.

  1979cited by this paper

• PD-1 cis-targeted IL-2v in combination with radiotherapy inhibits lung cancer growth and remodels the immune microenvironment

  2025influential citation
• Classification based on tumor phenotypes enables the novel molecular characterization of esophagogastric junction cancer

  2025cites this paper
• Systemic immunostimulation induces glucocorticoid-mediated thymic involution succeeded by rebound hyperplasia which is impaired in aged recipients

  2024cites this paper
• Development and validation of an immune‐related gene signature for prognosis in Lung adenocarcinoma

  2023cites this paper
• Ferroptosis Suppressor Protein 1 Inhibition Promotes Tumor Ferroptosis and Anti-tumor Immune Responses in Liver Cancer

  2023cites this paper
• Neoadjuvant vascular-targeted photodynamic therapy improves survival and reduces recurrence and progression in a mouse model of urothelial cancer

  2021cites this paper
• CD40 Agonist Targeted to Fibroblast Activation Protein α Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors

  2021cites this paper
• A Bayesian network meta‐analysis of comparison of cancer therapeutic vaccines for melanoma

  2021cites this paper
• The dark side of immunotherapy: pancreatic cancer

  2020cites this paper
• Microenvironment in Disease and Aging

  2020cites this paper
• The influence of the microbiota on immune development, chronic inflammation, and cancer in the context of aging

  2019cites this paper
• Molecular and metabolic pathways mediating curative treatment of a non-Hodgkin B cell lymphoma by Sindbis viral vectors and anti-4-1BB monoclonal antibody

  2019cites this paper
• OMIC signatures to understand cancer immunosurveillance and immunoediting: Melanoma and immune cells interplay in immunotherapy

  2019cites this paper
• The Regulatory Status Adopted by Lymph Node Dendritic Cells and T Cells During Healthy Aging Is Maintained During Cancer and May Contribute to Reduced Responses to Immunotherapy

  2018cites this paper
• Overcoming Barriers of Age to Enhance Efficacy of Cancer Immunotherapy: The Clout of the Extracellular Matrix

  2018cites this paper
• Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists

  2017cites this paper
• Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity

  2017cites this paper
• A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer

  2017cites this paper
• PD-1 and B7-H1 Expression after Show Differential Effects Correlating with T Cells + Regulatory and Conventional CD4

  2017cites this paper
• Combination immunotherapy: a road map The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

  2017cites this paper
• Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy

  2017cites this paper
• Cancer Immunotherapies: Are They as Effective in the Elderly?

  2017cites this paper
• Diacylglycerol Kinase ζ Limits Cytokine-dependent Expansion of CD8+ T Cells with Broad Antitumor Capacity

  2017cites this paper
• Combination immunotherapy: a road map

  2017cites this paper
• Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies

  2016cites this paper
• Adapting Cancer Immunotherapy Models for the Real World.

  2016cites this paper
• Novel approaches to improve DNA vaccine induced responses against difficult infectious disease targets

  2016cites this paper
• Adaptive Immunität durch T-Lymphozyten

  2016cites this paper
• Role of CD154 in cancer pathogenesis and immunotherapy.

  2015cites this paper
• Out-of-Sequence Signal 3 Paralyzes Primary CD4(+) T-Cell-Dependent Immunity.

  2015cites this paper
• Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 “Don't Eat Me” Signals

  2015cites this paper
• Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immunotherapy

  2015cites this paper
• Revisiting the paradigm on the putative need for antigen-specific responses in cancer

  2015cites this paper
• Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice

  2014influential citation
• Th1 cytokines are more effective than Th2 cytokines at licensing anti‐tumour functions in CD40‐activated human macrophages in vitro

  2014cites this paper
• Cell Death during IL-2/ Microenvironment Undergo Fas-Dependent Suppressor Cells in the Tumor Regulatory T Cells and Myeloid-Derived

  2014cites this paper
• The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40

  2014cites this paper
• Bystander Activation and Anti-Tumor Effects of CD8+ T Cells Following Interleukin-2 Based Immunotherapy Is Independent of CD4+ T Cell Help

  2014cites this paper
• The “Trojan Horse” Approach to Tumor Immunotherapy: Targeting the Tumor Microenvironment

  2014cites this paper
• Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials

  2014cites this paper
• Evaluation of the Safety and Biodistribution of M032, an Attenuated HSV-1 Virus Expressing hIL-12, After Intracerebral Administration to Aotus Non-Human Primates.

  2014cites this paper
• CD4⁺ and CD8⁺ T cell-dependent antiviral immunity requires STIM1 and STIM2.

  2014cites this paper
• Cytokine Intervention: A Double Edged Sword in the Nkg2d System Regulation

  2014cites this paper
• Evaluation of the Safety and Biodistribution of M032, an Attenuated Herpes Simplex Virus Type 1 Expressing hIL-12, After Intracerebral Administration to Aotus Nonhuman Primates

  2014cites this paper
• Regulatory T Cells and Myeloid-Derived Suppressor Cells in the Tumor Microenvironment Undergo Fas-Dependent Cell Death during IL-2/αCD40 Therapy

  2014cites this paper
• Impact of Obesity and Aging on the Tumor Immuno-Environment

  2013cites this paper
• Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma.

  2013cites this paper
• Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy

  2013cites this paper
• Immunoediting and Antigen Loss: Overcoming the Achilles Heel of Immunotherapy with Antigen Non-Specific Therapies

  2013cites this paper
• agonistic CD40 antibody administration transplant recipients from the lethal cytokine syndrome occurring after Alpha phenyl-tert-butyl nitrone (PBN) protects syngeneic marrow

  2013cites this paper
• Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity.

  2013cites this paper
• Chapter 34 – Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-arginine Metabolism in Immune Modulation

  2013cites this paper
• Immune co-signaling to treat cancer

  2013cites this paper
• dendritic cells: the Janus face of anti-CD40 Differential effect of agonistic anti-CD40 on human mature and immature

  2013cites this paper
• Combining chemotherapy with immunotherapy to treat mesothelioma : an investigation into the role of CD4+ T cells in a murine model

  2013cites this paper
• Dendritic Cells and Cancer: Development, Dysfunction and Therapeutic Targets

  2013cites this paper
• Impact of aging in cancer immunotherapy

  2013cites this paper
• The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8+ T cells into innate-like effector cells with antitumor activity

  2013cites this paper
• The role of antigen-specific and non-specific immunotherapy in the treatment of cancer

  2012cites this paper
• Mechanical Disruption of Tumors by Iron Particles and Magnetic Field Application Results in Increased Anti-Tumor Immune Responses

  2012cites this paper
• Delineation of antigen-specific and antigen-nonspecific CD8 (cid:1) memory T-cell responses after cytokine-based cancer immunotherapy

  2012cites this paper
• The Use of Agonistic Anti-CD40 Therapy in Treatments for Cancer

  2012cites this paper
• Agonistic Antibody to CD40 Boosts the Antitumor Activity of Adoptively Transferred T Cells In Vivo

  2012cites this paper
• Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T-cell responses after cytokine-based cancer immunotherapy.

  2012cites this paper
• Immunotherapeutic modulation of the suppressive liver and tumor microenvironments.

  2011cites this paper
• Revisiting the paradigm on the putative need for antigen-specific responses in cancer

  2011cites this paper
• Immunotherapy With Magentorheologic Fluids

  2011cites this paper
• Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy.

  2011cites this paper
• Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy

  2010cites this paper
• Targeting the tumor microenvironment with anti-neu/anti-CD40 conjugated nanoparticles for the induction of antitumor immune responses.

  2010cites this paper
• Advances in lupus stemming from the parent-into-F1 model.

  2010cites this paper
• Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer

  2010cites this paper
• Antigen specific memory T cells and their putative need for the generation of sustained anti-tumor responses.

  2010cites this paper
• Effects of cancer immunotherapy regimens on primary vs. secondary immune responses and the potential impact on long-term antitumor responses.

  2009cites this paper
• Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer

  2009cites this paper
• Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment

  2009influential citation
• Restoring Host Antitumoral Immunity: How Coregulatory Molecules Are Changing the Approach to the Management of Renal Cell Carcinoma

  2009cites this paper
• CD40 Stimulation and Antitumor Effects

  2009cites this paper
• Plasticity of T Cell Differentiation and Cytokine Signature: A Double-Edged Sword for Immune Responses

  2009cites this paper
• Deliberately provoking local inflammation drives tumors to become their own protective vaccine site.

  2008cites this paper
• Improvement in a Murine Model of Lupus Resulting in B Cell Elimination and Disease Outweigh B Cell-Stimulatory Effects CTL-Promoting Effects of CD 40 Stimulation

  2008cites this paper
• Regulatory and Conventional CD4+ T Cells Show Differential Effects Correlating with PD-1 and B7-H1 Expression after Immunotherapy12

  2008cites this paper
• Combined Anti-CD40 Conditioning and Well-timed Immunization Prolongs CD8+ T Cell Accumulation and Control of Established Brain Tumors

  2008cites this paper
• Wnt signaling in renal cancer.

  2008cites this paper
• Immunotherapy PD-1 and B 7-H 1 Expression after Show Differential Effects Correlating with T Cells + Regulatory and Conventional CD 4

  2008cites this paper
• Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice.

  2008cites this paper
• CTL-Promoting Effects of CD40 Stimulation Outweigh B Cell-Stimulatory Effects Resulting in B Cell Elimination and Disease Improvement in a Murine Model of Lupus1

  2008cites this paper
• Conjugation of CD40-binding peptide to glycol chitosan nanoparticle for localized delivery of tumor microenvironment modulator

  2008cites this paper
• Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-arginine Metabolism in Immune Modulation

  2007cites this paper
• Investigation of the therapeutic potential of transgenic CD40 ligand expression

  2007cites this paper
• Expression of CD40 and CD40L on tumor cells: the role of their interaction and new approach to immunotherapy.

  2007cites this paper
• IFN-γ mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy

  2007cites this paper
• Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity

  2007cites this paper
• Immunotherapy of cancer by IL-12-based cytokine combinations

  2007cites this paper
• Anti-CD40 Conditioning Enhances the TCD8 Response to a Highly Tolerogenic Epitope and Subsequent Immunotherapy of Simian Virus 40 T Antigen-Induced Pancreatic Tumors1

  2007cites this paper
• Synergistic In vivo Antitumor Effect of the Histone Deacetylase Inhibitor MS-275 in Combination with Interleukin 2 in a Murine Model of Renal Cell Carcinoma

  2007cites this paper
• Combination Therapy of an Orthotopic Renal Cell Carcinoma Model Using Intratumoral Vector-Mediated Costimulation and Systemic Interleukin-2

  2007cites this paper
• Costimulation, coinhibition and cancer.

  2007cites this paper
• Immunomodulation with CD40 Stimulation and Interleukin-2 Protects Mice from Disseminated Cryptococcosis

  2006cites this paper
• Stimulation through CD40 on Mouse and Human Renal Cell Carcinomas Triggers Cytokine Production, Leukocyte Recruitment, and Antitumor Responses that Can Be Independent of Host CD40 Expression12

  2006cites this paper